Results 161 to 170 of about 4,251 (181)

Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage

Biomedicine and Pharmacotherapy, 2020
Mohamed E Shaker, Hesham A M Gomaa, Khalid Saad Alharbi   +2 more
exaly  

Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy

British Journal of Clinical Pharmacology, 2022
Buyun Chen, Diansong Zhou, Shringi Sharma   +2 more
exaly  

Acalabrutinib in chronic lymphocytic leukemia

Expert Opinion on Pharmacotherapy, 2023
Martino, Enrica Antonia, Bruzzese, Antonella, Vigna, Ernesto, Iaccino, Enrico, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Filippelli, Gianfranco, Neri, Antonino, Morabito, Fortunato, Gentile, Massimo   +10 more
openaire   +2 more sources

Acalabrutinib (Zweitlinie)

2021
Wörmann, Bernhard, Wendtner, Clemens, Stilgenbauer, Stephan, Schetelig, Johannes, Eichhorst, Barbara, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +6 more
openaire   +1 more source

Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase

Toxicology and Applied Pharmacology, 2021
Yangliu Xia, Jun Cao, Yong Liu
exaly  

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis

Clinical Therapeutics, 2020
Matthew S Davids, Pauline Le Nouveau, Gautamjeet Singh   +2 more
exaly  

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Lancet, The, 2018
Michael Wang, Simon Rule, Pier Luigi Zinzani   +2 more
exaly  

Acalabrutinib/ibrutinib

Reactions Weekly, 2022
openaire   +1 more source

Acalabrutinib

Reactions Weekly, 2019
openaire   +1 more source

Acalabrutinib/ibrutinib

Reactions Weekly, 2023
openaire   +1 more source